Qkine appoints Thomas Scientific as new US Distribution Partner for its innovative growth factor and cytokine portfolio
Qkine, an industry-leading manufacturer of animal-free, highly pure recombinant proteins, is delighted to announce a sales distribution agreement with Thomas Scientific to enable fast and easy purchasing of Qkine growth factors and cytokines for stem cell scientists based in the United States.
Qkine appoints European distribution partner CliniSciences
Qkine appoints industry-leading CliniSciences as new European distributor for their growth factor and cytokine portfolio.
Qkine partners with the UK’s new £12M cellular agriculture manufacturing hub, CARMA, to revolutionize sustainable food production
Qkine is excited to announce a new partnernship with the UK’s new £12M cellular agriculture manufacturing hub, CARMA. The EPSRC-funded Cellular Agriculture Manufacturing Hub will develop new approaches to making food products.
Qkine announces collaboration with Sartorius
Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins, announces its collaboration with Sartorius, a global life science group, to supply growth factors and cytokines for stem cell and organoid research, as part of a comprehensive workflow solution.
Qkine and Sartorius partnership delivers a complete workflow solution for the analysis of advanced cell models
Cambridge, UK - Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins, is delighted to announce its collaboration with Sartorius, a global life science group, to supply growth factors and cytokines for stem cell and organoid research, as part of a comprehensive workflow solution.
Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities
Qkine is delighted to achieve ISO9001: 2015 certification, an internationally recognised standard that confirms its commitment to exceptional product quality, customer service and scientific support.
Qkine appoints Japanese distribution partner MBL to extend global availability of stem cell and organoid culture reagents
Qkine – UK-based specialist developer and manufacturer of proteins for stem cell and organoid culture – has extended its global reach through a sales distribution agreement with Japanese distribution partner, MBL Medical & Biological Laboratories Co Ltd (MBL). MBL has extensive knowledge and presence within the Japanese regenerative medicine sector.
Qkine and Enantis sign licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community
Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally. A core reagent for stem cell culture, this optimised form of the protein does not degrade in culture media, leading to a range of applications in enhanced weekend-free stem cell…
Three UK biotech companies combine research expertise in project funded by Innovate UK
Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK.
Qkine announces key appointments to strengthen leadership team in preparation for scaling commercial operations internationally
Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board strengthening the company’s leadership team in preparation for scaling commercial operations internationally.
Qkine secures £1.5M Series A funding from leading life science investors
Qkine today announced the successful closure of a £1.5M Series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team.
Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio
Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018.
Qkine backed by Cambridge Enterprise and a quintet of angels
University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed.